Artykuł w czasopiśmie
Brak miniatury
Licencja

CC-BYCC-BY - Uznanie autorstwa
 

Structural characterisation of inhibitory and non-inhibitory MMP-9–TIMP-1 complexes and implications for regulatory mechanisms of MMP-9

Uproszczony widok
dc.abstract.enMMP‐9 plays a number of important physiological functions but is also responsible for many pathological processes, including cancer invasion, metastasis, and angiogenesis. It is, therefore, crucial to understand its enzymatic activity, including activation and inhibition mechanisms. This enzyme may also be partially involved in the “cytokine storm” that is characteristic of COVID‐19 disease (SARS‐CoV‐2), as well as in the molecular mechanisms responsible for lung fibrosis. Due to the variety of processing pathways involving MMP‐9 in biological systems and its uniqueness due to the O‐glycosylated domain (OGD) and fibronectin‐like (FBN) domain, specific interactions with its natural TIMP‐1 inhibitor should be carefully studied, because they differ significantly from other homologous systems. In particular, earlier experimental studies have indicated that the newly characterised circular form of a proMMP‐9 homotrimer exhibits stronger binding properties to TIMP‐1 compared to its monomeric form. However, molecular structures of the complexes and the binding mechanisms remain unknown. The purpose of this study is to fill in the gaps in knowledge. Molecular modelling methods are applied to build the inhibitory and non‐inhibitory MMP‐9–TIMP‐1 complexes, which allows for a detailed description of these structures and should allow for a better understanding of the regulatory processes in which MMP‐9 is involved.
dc.affiliationUniwersytet Warszawski
dc.contributor.authorCharzewski, Łukasz
dc.contributor.authorLesyng, Bogdan
dc.contributor.authorKrzyśko, Krystiana
dc.date.accessioned2024-01-26T08:21:19Z
dc.date.available2024-01-26T08:21:19Z
dc.date.copyright2021-05-12
dc.date.issued2021
dc.description.accesstimeAT_PUBLICATION
dc.description.financeŚrodki finansowe, o których mowa w art. 365 pkt. 2 ustawy
dc.description.number1
dc.description.versionFINAL_PUBLISHED
dc.description.volume11
dc.identifier.doi10.1038/S41598-021-92881-X
dc.identifier.issn2045-2322
dc.identifier.urihttps://repozytorium.uw.edu.pl//handle/item/120880
dc.identifier.weblinkhttp://www.nature.com/articles/s41598-021-92881-x.pdf
dc.languageeng
dc.pbn.affiliationphysical sciences
dc.relation.ispartofScientific Reports
dc.relation.pages13376-13388
dc.rightsCC-BY
dc.sciencecloudnosend
dc.subject.enMMP-9
dc.subject.enTIMP-1
dc.subject.enmodelling
dc.subject.enMM
dc.subject.enMD
dc.subject.enstructure
dc.subject.encomplex
dc.subject.encircular form
dc.subject.enhomotrimer
dc.subject.eninhibition
dc.subject.enCOVID-19
dc.subject.enfibrosis
dc.titleStructural characterisation of inhibitory and non-inhibitory MMP-9–TIMP-1 complexes and implications for regulatory mechanisms of MMP-9
dc.typeJournalArticle
dspace.entity.typePublication